292 related articles for article (PubMed ID: 34831015)
21. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
Li Y; Song Q; Day BW
Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
[TBL] [Abstract][Full Text] [Related]
22. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
23. Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma.
Meerang M; Bérard K; Felley-Bosco E; Lauk O; Vrugt B; Boss A; Kenkel D; Broggini-Tenzer A; Stahel RA; Arni S; Weder W; Opitz I
Mol Cancer Ther; 2016 May; 15(5):1095-105. PubMed ID: 26839306
[TBL] [Abstract][Full Text] [Related]
24. Hedgehog signaling is synergistically enhanced by nutritional deprivation and ligand stimulation in human fibroblasts of Gorlin syndrome.
Mizuochi H; Fujii K; Shiohama T; Uchikawa H; Shimojo N
Biochem Biophys Res Commun; 2015 Feb; 457(3):318-23. PubMed ID: 25576868
[TBL] [Abstract][Full Text] [Related]
25. Targeting the Hedgehog Pathway for Locally Advanced and Metastatic Basal Cell Carcinoma.
Yin VT; Esmaeli B
Curr Pharm Des; 2017; 23(4):655-659. PubMed ID: 27928965
[TBL] [Abstract][Full Text] [Related]
26. Basal Cell Carcinoma in Gorlin's Patients: a Matter of Fibroblasts-Led Protumoral Microenvironment?
Gache Y; Brellier F; Rouanet S; Al-Qaraghuli S; Goncalves-Maia M; Burty-Valin E; Barnay S; Scarzello S; Ruat M; Sevenet N; Avril MF; Magnaldo T
PLoS One; 2015; 10(12):e0145369. PubMed ID: 26694869
[TBL] [Abstract][Full Text] [Related]
27. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
28. Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma.
Kuonen F; Huskey NE; Shankar G; Jaju P; Whitson RJ; Rieger KE; Atwood SX; Sarin KY; Oro AE
J Invest Dermatol; 2019 Jul; 139(7):1439-1448. PubMed ID: 30707899
[TBL] [Abstract][Full Text] [Related]
29. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study.
Dummer R; Guminksi A; Gutzmer R; Lear JT; Lewis KD; Chang ALS; Combemale P; Dirix L; Kaatz M; Kudchadkar R; Loquai C; Plummer R; Schulze HJ; Stratigos AJ; Trefzer U; Squittieri N; Migden MR
Br J Dermatol; 2020 Jun; 182(6):1369-1378. PubMed ID: 31545507
[TBL] [Abstract][Full Text] [Related]
30. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
[TBL] [Abstract][Full Text] [Related]
31. Sonic hedgehog signaling in Basal cell nevus syndrome.
Athar M; Li C; Kim AL; Spiegelman VS; Bickers DR
Cancer Res; 2014 Sep; 74(18):4967-75. PubMed ID: 25172843
[TBL] [Abstract][Full Text] [Related]
32. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
33. Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome).
Bresler SC; Padwa BL; Granter SR
Head Neck Pathol; 2016 Jun; 10(2):119-24. PubMed ID: 26971503
[TBL] [Abstract][Full Text] [Related]
34. Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib.
Yoon J; Apicelli AJ; Pavlopoulos TV
JAAD Case Rep; 2018 Jan; 4(1):10-12. PubMed ID: 29387745
[No Abstract] [Full Text] [Related]
35. Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness.
Silapunt S; Chen L; Migden MR
Ther Adv Med Oncol; 2016 Sep; 8(5):375-82. PubMed ID: 27583029
[TBL] [Abstract][Full Text] [Related]
36. Long-term Response to Vismodegib in a Patient with Gorlin-Goltz Syndrome: A Case Report and Review of Pathological Mechanisms Involved.
Kesireddy M; Mendiola VL; Jana B; Patel S
Cureus; 2019 Aug; 11(8):e5383. PubMed ID: 31616614
[TBL] [Abstract][Full Text] [Related]
37. PTCH1 mutation is a frequent event in oesophageal basaloid squamous cell carcinoma.
Saito T; Mitomi H; Imamhasan A; Hayashi T; Kurisaki-Arakawa A; Mitani K; Takahashi M; Kajiyama Y; Yao T
Mutagenesis; 2015 Mar; 30(2):297-301. PubMed ID: 25395299
[TBL] [Abstract][Full Text] [Related]
38. Discovery and preclinical development of vismodegib.
Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
[TBL] [Abstract][Full Text] [Related]
39. Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma.
Doan HQ; Silapunt S; Migden MR
Onco Targets Ther; 2016; 9():5671-5678. PubMed ID: 27695345
[TBL] [Abstract][Full Text] [Related]
40. Vismodegib hedgehog-signaling inhibition and treatment of basal cell carcinomas as well as keratocystic odontogenic tumors in Gorlin syndrome.
Booms P; Harth M; Sader R; Ghanaati S
Ann Maxillofac Surg; 2015; 5(1):14-9. PubMed ID: 26389028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
